ABOS News and Press, Acumen Pharmaceuticals Inc. From 03/20/23

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 20, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today...

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 08, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, a...

CHARLOTTESVILLE, Va. and CARMEL, Ind., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers...

CHARLOTTESVILLE, Va. and CARMEL, Ind., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s...

Summary Today, we put Acumen Pharmaceuticals in the spotlight for the first time. The stock of this Alzheimer's focused developmental concern is trading near its net cash on the balance sheet. An investment analysis follows in the paragraphs below. For further ...

Acumen Pharmaceuticals, Inc. (ABOS) Q3 2022 Earnings Conference Call November 14, 2022 04:30 PM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - CMO Matt Zuga - CFO and CBO Conference Call Participants ...

The following slide deck was published by Acumen Pharmaceuticals, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Acumen Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call Presentation

Acumen Pharmaceuticals press release ( NASDAQ: ABOS ): Q3 GAAP EPS of -$0.26. Cash, cash equivalents and marketable securities of $200.2 million as of Sept. 30, 2022. For further details see: Acumen Pharmaceuticals GAAP EPS of -$0.26

INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease continues to progress Acumen anticipates completing enrollment in the first quarter of 2023 and reporting topline data from this trial in the second half of 2023 ACU193 w...

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer’s disease, announced today that management will...